Abstract
Background: We previously demonstrated that NO pathway overexpression by phosphodiesterase 5 (PDE5) inhibition with sildenafil acutely improves gas exchange and exercise performance in heart failure patients (HF). This study assesses the impact of chronic sildenafil therapy on gas exchange, exercise performance and quality of life in patients with stable HF. Methods: According to a double-blind, placebo-controlled design, 22 stable HF patients (NYHA Class II-III) with systolic dysfunction (average left ventricular ejection fraction: 36 ± 4 %) were randomly assigned (1:1) to receive placebo or sildenafil (25 mg, 3 times/day) for six months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
